A Blowout Call on Biotech Select

Editor's Desk

David Morrow

01/27/09 - 02:28 PM EST

I have two simple goals with this brief missive: Give well-deserved kudos to Adam Feuerstein for his call on CV Therapeutics(CVTX Quote) that he recently added to the portfolio of Biotech Select, a premium service from TheStreet.com. And second, if you're interested in biotech stocks, you should subscribe to Biotech Select.

Adam added CV Therapeutics to the model portfolio of Biotech Select on Jan. 20, when the stock was trading at $10.75 a share. Shares of CVTX rose to $16.68 in intraday trading today on news that the company had received and rejected a $16-per-share takeover offer from Japanese drugmaker Astellas.

Subscribers of Biotech Select who followed Feuerstein's buy suggestion gained more than 50% from this position in just five trading days!

Nice work, Adam. Click here to take a free trial to Biotech Select and receive all of Adam's commentary and stock recommendations.

Let's stay interactive.

Dave Morrow

Editor-in-Chief

Visit TheStreet for more great features

TheStreet Premium Services

From the action-oriented investing ideas of Action Alerts PLUS by Jim Cramer to the expert technical trading strategies of Helene Meisler's Top Stocks, TheStreet.com offers a range of premium services to help boost your portfolio's performance. View now.

Expert Advisors Alerts Delivered to your Inbox

Action Alerts PLUS: Cramer's personal portfolio, emails before he acts.

RealMoney: 70+ experts share their top investing ideas and analysis.

Stocks Under $10: Alerts identify undervalued stocks with profit potential.

FREE NEWSLETTERS

Get an edge on the market with the help of free email newsletters like Jim Cramer's Daily Booyah!. Learn about the day's major market events, companies that sizzled or fizzled and lots more that can help you make more profitable investing decisions. Sign up.